MARKET

VTGN

VTGN

Vistagen Therapeutics Inc
NASDAQ
0.1326
-0.0086
-6.09%
After Hours: 0.1361 +0.0035 +2.64% 19:48 06/02 EDT
OPEN
0.1412
PREV CLOSE
0.1412
HIGH
0.1420
LOW
0.1300
VOLUME
4.27M
TURNOVER
0
52 WEEK HIGH
1.200
52 WEEK LOW
0.0768
MARKET CAP
29.08M
P/E (TTM)
-0.4301
1D
5D
1M
3M
1Y
5Y
Vistagen Therapeutics Inc: Current report
Press release · 2d ago
Vistagen Presents Fasedienol Safety And Exploratory Efficacy Data From Phase 3 Open-Label Social Anxiety Disorder Study At American Society For Clinical Psychopharmacology Annual Meeting
Benzinga · 2d ago
Crude Oil Down 2%; Donaldson Shares Drop Following Q3 Results
Benzinga · 3d ago
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 3d ago
Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views
Benzinga · 3d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 3d ago
Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
Vistagen To Present Fasedienol Safety And Exploratory Efficacy Data From Phase 3 Open-Label Social Anxiety Disorder Study At American Society For Clinical Psychopharmacology Annual Meeting
Benzinga · 4d ago
More
About VTGN
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. Its AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), which is a potent and selective full antagonist of the glycine co-agonist site of the N-methyl-D-aspartate receptor (NMDAR) that inhibits the function of the NMDAR, an ionotropic glutamate receptor in the brain.

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.